In summary, our findings underscore the valuable role of the HALP score as a simple, accessible and cost-effective biomarker that integrates nutritional and inflammatory status to help predict the risk of CIN in patients undergoing coronary interventions. This evidence concerns the gene NAT10 and cervical squamous intraepithelial neoplasia.